The FDA Center for Veterinary Medicine (CVM) published in the Federal Register a notice of “request for information” from “the public, particularly veterinarians, related to the use of cannabis-derived products (CDPs) in animals, with an emphasis on cannabidiol (CBD) products“.
Specifically, the FDA CVM is asking for “usage trends ( e.g., product selection, indications, etc.), quality standards, benefits of use, potential drug interactions, 
adverse events and safety problems, and toxicological concerns.“
“CVM is particularly interested in input from practicing veterinarians, whose expertise and experience can help inform FDA regarding the use and effect of CDPs in animals. FDA is gathering information relating to the use of CDPs in animals, with an emphasis on CBD products and other hemp-derived products and general trends associated with those products.” FDA CVM stated this request will help the agency understand safety of CBD products, “in addition to aiding our understanding of veterinarians’ experiences related to the use of CDPs for their animal patients.”
[Here is a link to the US Federal Register]